Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis.
There are no experimental studies regarding the prophylactic efficacy of linezolid against infective endocarditis. Nonbacterial thrombotic endocarditis of the aortic valve was induced in rabbits by the insertion of a polyethylene catheter. Twenty-four hours later, animals were randomly assigned to a control group, and groups receiving either ampicillin (two doses of 40 mg/kg of body weight each, given intravenously, 2 h apart) or linezolid (a single per os dose of 75 mg/kg). The first dose of ampicillin and the single dose of linezolid were administered 0.5 and 1 h, respectively, prior to the intravenous inoculation of approximately 10(7) CFU of Streptococcus oralis or Enterococcus faecalis. Linezolid peak levels in rabbit serum were similar to the peak serum levels in humans following a 600-mg oral dose of linezolid. Linezolid prevented endocarditis in 87% of S. oralis-challenged rabbits (P < 0.001 versus controls; P = 0.026 versus ampicillin). In rabbits challenged with E. faecalis, linezolid prevented endocarditis in 73% (P = 0.003 versus controls; P = 0.049 versus ampicillin). Ampicillin prevented endocarditis due to S. oralis or due to E. faecalis in 47% (P = 0.005 versus controls) and in 30% (P = not significant versus controls) of the challenged animals, respectively. In conclusion, linezolid was effective as prophylaxis against endocarditis caused by a strain of S. oralis and to a lesser degree against that caused by a strain of E. faecalis. Its prophylactic efficacy was superior to that of ampicillin.
Athanassopoulos
George
G
Fourth Department of Internal Medicine, General Hospital Attikon, Athens University School of Medicine, Athens, Greece.
Pefanis
Angelos
A
Sakka
Vissaria
V
Iliopoulos
Dimitrios
D
Perrea
Despina
D
Giamarellou
Helen
H
D000081:Acetamides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D001021:Aortic Valve; D004697:Endocarditis, Bacterial / Q000517:prevention & control*; D013293:Enterococcus faecalis; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000517:prevention & control*; D006349:Heart Valve Diseases / Q000517:prevention & control*; D000069349:Linezolid; D023303:Oxazolidinones / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011817:Rabbits; D013290:Streptococcal Infections / Q000517:prevention & control*
D000081:Acetamides; D023303:Oxazolidinones; D000069349:Linezolid